復星醫藥(600196.SH):復星醫藥產業擬7.42億元受讓重慶藥友約10.044%股權
格隆匯9月8日丨復星醫藥(600196.SH)公佈,2020年9月8日,控股子公司復星醫藥產業與職工持股會簽訂《股權轉讓協議》,復星醫藥產業擬以人民幣7.42億元受讓職工持股會所持重慶藥友約10.044%的股權。本次交易完成後,復星醫藥產業將合計持有重慶藥友約61.044%的股權,重慶藥友仍為公司控股子公司。本次交易有利於進一步優化重慶藥友的治理結構、提高其經營效率;同時,集團於重慶藥友持股比例的提升,有利於加強集團生產、人才及其他資源的整合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.